In this prospective observational study, we compare the efficacy of glecaprevir/pibrentasvir vs sofosbuvir/velpatasvir in treating hepatitis C within a unique model of care utilizing a combination of telehealth, an ambulatory van, case management, and a contracted pharmacy. Among 769 patients treated, 90.4% completed treatment, with 9.6% lost to follow-up. Both regimens demonstrated high completion rates and efficacy.
Keywords: glecaprevir/pibrentasvir; hepatitis C; sofosbuvir/velpatasvir.
© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.